Key facts
- iPS PORTAL’s last known valuation is $42.3M (Dec 2025).
- It has raised $33.7M; the latest was Later Stage VC in Mar 2026.
- Notable investors include SMBC Venture Capital, Ajinomoto, Chugai Pharmaceutical, Daiichi Jitsugyo, Daiwa Securities Group — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for iPS PORTAL
- ·The full record, as it builds
Funding rounds
No funding rounds for iPS PORTAL are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iPS PORTAL
Provider of research and development outsourcing services intended to support the practical application of induced pluripotent stem cell technology. The company's services include offering support for research, contract testing, development, and concept planning, and offering training programs in the field of cell culture to researchers, enabling healthcare companies to accelerate research and commercialization of drug discovery and regenerative medicine.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2014
- Employees
- 20
- Website
- ipsportal.com/
- Ownership
- Privately Held (backing)
iPS PORTAL doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iPS PORTAL shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iPS PORTAL in its N-PORT filings yet. We sweep new filings monthly.